Pictured: CVS Health’s signage outside its office in Texas/iStock, JHVEPhoto
Prescriptions for biosimilar versions of AbbVie’s Humira (adalimumab) have spiked to 36% after leading pharmacy benefit manager CVS Caremark removed the branded reference product from its major national commercial formularies, according to…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
